{"product_id":"molecular-biotechnology-principles-and-applications-of-recombinant-dna-hardback-9781683673644","title":"Molecular Biotechnology; Principles and Applications of Recombinant DNA (Hardback) 9781683673644","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eMolecular Biotechnology\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003ePrinciples and Applications of Recombinant DNA\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eBernard R. Glick (Author), Cheryl L. Patten (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781683673644, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 3 March 2022\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e896 pages\u003cbr\u003e27.9 x 22.1 x 4.1 cm, 2.087 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eAn authoritative introduction to the fast-changing world of molecular biotechnology \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIn continuous publication since 1994 and now in its sixth edition, \u003ci\u003eMolecular Biotechnology: Principles and Applications of Recombinant DNA\u003c\/i\u003e has been effective in introducing this complex field to students for more than 25 years. This textbook covers essentially every aspect of the field of molecular biotechnology, which is constantly changing and adapting in light of new advances.\u003c\/p\u003e \u003cp\u003eThis edition includes the latest techniques in DNA sequencing and genetic engineering of microbial, plant, and animal genomes, including human genome editing, as well as updates across many areas, such as:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eImmunological assays for disease diagnosis, more effective bacteriophage therapy, and new ways of dealing with antibiotic-resistant bacteria\u003c\/li\u003e \u003cli\u003eNew and developing vaccines for influenza, tuberculosis, and emerging viral threats, including Zika and SARS-CoV-2\u003c\/li\u003e \u003cli\u003eEngineering bacteria to perform plastic degradation and green algae to produce hydrogen, altering amino acid biosynthesis, and creating designer cellulosomes\u003c\/li\u003e \u003cli\u003eProduction of humanized monoclonal antibodies in plants, modifying hybrid plants to produce clonal hybrids, and protecting plants from viral and fungal diseases\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003eMolecular Biotechnology\u003c\/i\u003e features nearly 600 detailed figures and is an ideal textbook for undergraduate and graduate courses in introductory biotechnology, as well as courses dedicated to utilizing this technology, such as medical, agricultural, environmental, and industrial biotechnology applications.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003e1.The Development of Molecular Biotechnology 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEmergence of Molecular Biotechnology 1\u003c\/p\u003e \u003cp\u003eRecombinant DNA Technology 3\u003c\/p\u003e \u003cp\u003eCommercialization of Molecular Biotechnology 6\u003c\/p\u003e \u003cp\u003eConcerns and Consequences 8\u003c\/p\u003e \u003cp\u003eSummary 10\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003eReview Questions 11\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2.Fundamental Technologies 13\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMolecular Cloning 13\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePreparation of DNA for Cloning 13\u003c\/p\u003e \u003cp\u003eInsertion of Target DNA into a Plasmid Vector 18\u003c\/p\u003e \u003cp\u003eTransformation and Selection of Cloned DNA in a Bacterial Host 21\u003c\/p\u003e \u003cp\u003eCloning Eukaryotic Genes 26\u003c\/p\u003e \u003cp\u003eRecombinational Cloning 30\u003c\/p\u003e \u003cp\u003eGenomic Libraries 32\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGenome Engineering Using CRISPR Technology 36\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePolymerase Chain Reaction 39\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAmplification of DNA by PCR 39\u003c\/p\u003e \u003cp\u003eCloning PCR Products 42\u003c\/p\u003e \u003cp\u003eQuantitative PCR 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChemical Synthesis of Genes 46\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAssembling Oligonucleotides into Genes 46\u003c\/p\u003e \u003cp\u003eAssembling PCR Products into Genes 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDNA Sequencing Technologies 48\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDideoxynucleotide Sequencing 50\u003c\/p\u003e \u003cp\u003eSequencing Using Reversible Chain Terminators 53\u003c\/p\u003e \u003cp\u003eSingle‐Molecule Real‐Time Sequencing 55\u003c\/p\u003e \u003cp\u003eNanopore Sequencing 56\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSequencing Whole Genomes 56\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePreparation of Genomic DNA Sequencing Libraries 57\u003c\/p\u003e \u003cp\u003eHigh‐Throughput Next‐Generation Sequencing 59\u003c\/p\u003e \u003cp\u003eGenome Sequence Assembly 60\u003c\/p\u003e \u003cp\u003eSequencing Metagenomes 61\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGenomics 62\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTranscriptomics 65\u003c\/p\u003e \u003cp\u003eProteomics 70\u003c\/p\u003e \u003cp\u003eMetabolomics 84\u003c\/p\u003e \u003cp\u003eSummary 86\u003c\/p\u003e \u003cp\u003eReferences 87\u003c\/p\u003e \u003cp\u003eReview Questions 89\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3.Production of Recombinant Proteins 91\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProtein Production in Prokaryotic Hosts 91\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRegulating Transcription 92\u003c\/p\u003e \u003cp\u003eIncreasing Translation Efficiency 96\u003c\/p\u003e \u003cp\u003eIncreasing Protein Stability 100\u003c\/p\u003e \u003cp\u003eIncreasing Protein Secretion 105\u003c\/p\u003e \u003cp\u003eFacilitating Protein Purification 111\u003c\/p\u003e \u003cp\u003eIntegrating DNA into the Host Chromosome 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHeterologous Protein Production in Eukaryotic Cells 119\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePosttranslational Modification of Eukaryotic Proteins 120\u003c\/p\u003e \u003cp\u003eGeneral Features of Eukaryotic Expression Systems 123\u003c\/p\u003e \u003cp\u003eYeast Expression Systems 123\u003c\/p\u003e \u003cp\u003eBaculovirus–Insect Cell Expression Systems 137\u003c\/p\u003e \u003cp\u003eMammalian Cell Expression Systems 145\u003c\/p\u003e \u003cp\u003eProtein Engineering 156\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDirected Mutagenesis 156\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRandom Mutagenesis 161\u003c\/p\u003e \u003cp\u003eExamples of Protein Engineering 164\u003c\/p\u003e \u003cp\u003eSummary 173\u003c\/p\u003e \u003cp\u003eReferences 174\u003c\/p\u003e \u003cp\u003eReview Questions 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4.Molecular Diagnostics 179\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eImmunological Approaches To Detect Protein Biomarkers 180\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAntibodies 180\u003c\/p\u003e \u003cp\u003eAgglutination 185\u003c\/p\u003e \u003cp\u003eEnzyme‐Linked Immunosorbent Assays 186\u003c\/p\u003e \u003cp\u003eProtein Arrays To Detect Polygenic Diseases 194\u003c\/p\u003e \u003cp\u003eImmunoassays for Protein Conformation‐Specific Disorders 197\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDNA\u003c\/b\u003e\u003cb\u003e‐\u003c\/b\u003e\u003cb\u003eBased Diagnostic Approaches 199\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHybridization Probes 199\u003c\/p\u003e \u003cp\u003ePCR‐Based Detection Methods 207\u003c\/p\u003e \u003cp\u003eCRISPR‐Cas‐Based Diagnostic Assays 218\u003c\/p\u003e \u003cp\u003eDNA Microarrays 219\u003c\/p\u003e \u003cp\u003eWhole‐Genome Sequencing To Assess Genetic Disease Risk 225\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDetecting RNA Signatures of Disease 226\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDetection of Disease‐Associated Changes in Gene Expression 227\u003c\/p\u003e \u003cp\u003eDetection of RNA Signatures of Antibiotic Resistance in Bacteria 228\u003c\/p\u003e \u003cp\u003eDetection of miRNA Signatures of Disease 230\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBiofluorescent and Bioluminescent Systems 233\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFluorescent Proteins 233\u003c\/p\u003e \u003cp\u003eLuciferase 234\u003c\/p\u003e \u003cp\u003eMicrobial Biosensors 235\u003c\/p\u003e \u003cp\u003eSummary 238\u003c\/p\u003e \u003cp\u003eReferences 239\u003c\/p\u003e \u003cp\u003eReview Questions 241\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5.Protein Therapeutics 243\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePharmaceuticals 244\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHuman Interferons 244\u003c\/p\u003e \u003cp\u003eHuman Growth Hormone 248\u003c\/p\u003e \u003cp\u003eTumor Necrosis Factor Alpha 251\u003c\/p\u003e \u003cp\u003eExtending Protein Half-Life 252\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEnzymes 253\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDNase I 253\u003c\/p\u003e \u003cp\u003eAlginate Lyase 254\u003c\/p\u003e \u003cp\u003ePhenylalanine Ammonia Lyase 258\u003c\/p\u003e \u003cp\u003eα1 -Antitrypsin 259\u003c\/p\u003e \u003cp\u003eGlycosidases 261\u003c\/p\u003e \u003cp\u003eMasking Nonhuman Epitopes 263\u003c\/p\u003e \u003cp\u003eToxin-Intein Fusions 264\u003c\/p\u003e \u003cp\u003eTargeting Mitochondria 265\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBacteria and Therapeutics 267\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eInterleukin-10 270\u003c\/p\u003e \u003cp\u003eLeptin 272\u003c\/p\u003e \u003cp\u003eAn HIV Inhibitor 274\u003c\/p\u003e \u003cp\u003eInsulin 276\u003c\/p\u003e \u003cp\u003eParkinson’s Disease 279\u003c\/p\u003e \u003cp\u003eCancer and Bacteria 279\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRecombinant Antibodies 280\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHybrid Human–Mouse Monoclonal Antibodies 284\u003c\/p\u003e \u003cp\u003eHuman Monoclonal Antibodies 287\u003c\/p\u003e \u003cp\u003eAntibody Fragments 289\u003c\/p\u003e \u003cp\u003eCombinatorial Libraries of Antibody Fragments 294\u003c\/p\u003e \u003cp\u003eA Combinatorial Library of Full-Length Antibodies 297\u003c\/p\u003e \u003cp\u003eShuffling CDR Sequences 298\u003c\/p\u003e \u003cp\u003eDual-Variable-Domain Antibodies 298\u003c\/p\u003e \u003cp\u003eBispecific Antibodies against Hemophilia 300\u003c\/p\u003e \u003cp\u003eAnti-HIV Antibodies 300\u003c\/p\u003e \u003cp\u003eAnticancer Antibodies 302\u003c\/p\u003e \u003cp\u003eAntibodies against Various Diseases 309\u003c\/p\u003e \u003cp\u003eAntiobesity Antibodies 313\u003c\/p\u003e \u003cp\u003eEnhanced Antibody Half-Life 315\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAffibody Molecules 315\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSummary 318\u003c\/p\u003e \u003cp\u003eReferences 318\u003c\/p\u003e \u003cp\u003eReview Questions 322\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. Nucleic Acids as Therapeutic Agents 325\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTargeting Specific mRNA and DNA Sequences 327\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAntisense RNA 327\u003c\/p\u003e \u003cp\u003eAptamers 331\u003c\/p\u003e \u003cp\u003eRibozymes and DNAzymes 338\u003c\/p\u003e \u003cp\u003eInterfering RNA 341\u003c\/p\u003e \u003cp\u003eZinc Finger Nucleases 348\u003c\/p\u003e \u003cp\u003eCRISPR‐Cas System 349\u003c\/p\u003e \u003cp\u003eNanozymes 351\u003c\/p\u003e \u003cp\u003eNanoparticles 352\u003c\/p\u003e \u003cp\u003eEngineering Bacteriophages 352\u003c\/p\u003e \u003cp\u003e\u003cb\u003eViral Delivery Systems 357\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNonviral Delivery Systems 365\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDirect Injection 365\u003c\/p\u003e \u003cp\u003eLipids 367\u003c\/p\u003e \u003cp\u003eBacteria 369\u003c\/p\u003e \u003cp\u003eDendrimers 372\u003c\/p\u003e \u003cp\u003eAntibodies 373\u003c\/p\u003e \u003cp\u003eAptamers 373\u003c\/p\u003e \u003cp\u003eTransposons 374\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGene Therapy 376\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMitochondrial Diseases 378\u003c\/p\u003e \u003cp\u003eProdrug Activation Therapy 378\u003c\/p\u003e \u003cp\u003ePromoterless Gene Targeting 379\u003c\/p\u003e \u003cp\u003eSummary 382\u003c\/p\u003e \u003cp\u003eReferences 382\u003c\/p\u003e \u003cp\u003eReview Questions 386\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Vaccines 387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVaccination 387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCurrent and Future Vaccines 389\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSubunit and Peptide Vaccines 392\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHerpes Simplex Virus 393\u003c\/p\u003e \u003cp\u003eBovine Herpes Virus-1 394\u003c\/p\u003e \u003cp\u003eCholera 396\u003c\/p\u003e \u003cp\u003eInfluenza 396\u003c\/p\u003e \u003cp\u003eSARS 397\u003c\/p\u003e \u003cp\u003eCOVID-19 399\u003c\/p\u003e \u003cp\u003eStaphylococcus aureus 401\u003c\/p\u003e \u003cp\u003eHuman Papillomavirus 402\u003c\/p\u003e \u003cp\u003eFoot-and-Mouth Virus 404\u003c\/p\u003e \u003cp\u003eStreptococcus 405\u003c\/p\u003e \u003cp\u003ePeptides 407\u003c\/p\u003e \u003cp\u003eMalaria 408\u003c\/p\u003e \u003cp\u003eDelivery 411\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGenetic Immunization: DNA Vaccines 414\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDelivery 414\u003c\/p\u003e \u003cp\u003eCancer 422\u003c\/p\u003e \u003cp\u003eZika Virus 422\u003c\/p\u003e \u003cp\u003eDental Caries 423\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEngineered Attenuated Vaccines 424\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHerpes Simplex Virus 425\u003c\/p\u003e \u003cp\u003eCholera 426\u003c\/p\u003e \u003cp\u003eSalmonella Species 428\u003c\/p\u003e \u003cp\u003eLeishmania Species 430\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVector Vaccines 430\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eVaccines Directed against Viruses 430\u003c\/p\u003e \u003cp\u003eVaccines Directed against Bacteria 441\u003c\/p\u003e \u003cp\u003eBacteria as Antigen Delivery Systems 444\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMonoclonal Antibody Passive Immunity 449\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eInfluenza Virus 450\u003c\/p\u003e \u003cp\u003eSummary 452\u003c\/p\u003e \u003cp\u003eReferences 452\u003c\/p\u003e \u003cp\u003eReview Questions 456\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Industrial and Environmental Uses of Recombinant Microorganisms 459\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRestriction Endonucleases 459\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSmall Biological Molecules 461\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003el-Ascorbic Acid 463\u003c\/p\u003e \u003cp\u003eIndigo 467\u003c\/p\u003e \u003cp\u003eAmino Acids 468\u003c\/p\u003e \u003cp\u003eLycopene 473\u003c\/p\u003e \u003cp\u003eAntibiotics 474\u003c\/p\u003e \u003cp\u003eBiopolymers 487\u003c\/p\u003e \u003cp\u003eSolvent Tolerance 493\u003c\/p\u003e \u003cp\u003eSystems Metabolic Engineering To Optimize Product Yield 494\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMicrobial Degradation of Xenobiotics 496\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGenetic Engineering of Biodegradative Pathways 497\u003c\/p\u003e \u003cp\u003ePlastics 507\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUtilization of Starch and Sugars 508\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCommercial Production of Fructose and Alcohol 508\u003c\/p\u003e \u003cp\u003eIncreasing Alcohol Production 510\u003c\/p\u003e \u003cp\u003eImproving Fructose Production 517\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUtilization of Cellulose and Hemicellulose 518\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eLignocellulosics 519\u003c\/p\u003e \u003cp\u003eCellulase Genes 522\u003c\/p\u003e \u003cp\u003eDirect Conversion of Biomass to Ethanol 530\u003c\/p\u003e \u003cp\u003eAlcohol Production by Zymomonas mobilis 531\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLipids from Cyanobacteria 534\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHydrogen Production 535\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSummary 538\u003c\/p\u003e \u003cp\u003eReferences 539\u003c\/p\u003e \u003cp\u003eReview Questions 542\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Large-Scale Production of Proteins and Nucleic Acids from Recombinant Microorganisms 545\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePrinciples of Microbial Growth 547\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBatch Fermentation 548\u003c\/p\u003e \u003cp\u003eFed-Batch Fermentation 549\u003c\/p\u003e \u003cp\u003eContinuous Fermentation 550\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMaximizing the Efficiency of the Fermentation Process 551\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHigh-Density Cell Cultures 552\u003c\/p\u003e \u003cp\u003eIncreasing Plasmid Stability 555\u003c\/p\u003e \u003cp\u003eQuiescent E. coli Cells 555\u003c\/p\u003e \u003cp\u003eProtein Secretion 558\u003c\/p\u003e \u003cp\u003eReducing Acetate 558\u003c\/p\u003e \u003cp\u003eImproving Antibody Production in E. coli 561\u003c\/p\u003e \u003cp\u003e\u003cb\u003eBioreactors 561\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTypical Large-Scale Fermentation Systems 565\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTwo-Stage Fermentation in Tandem Airlift Reactors 566\u003c\/p\u003e \u003cp\u003eTwo-Stage Fermentation in a Single Stirred-Tank Reactor 568\u003c\/p\u003e \u003cp\u003eBatch versus Fed-Batch Fermentation 569\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHarvesting Microbial Cells 574\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDisrupting Microbial Cells 576\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDownstream Processing 578\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eInclusion Bodies 579\u003c\/p\u003e \u003cp\u003eUtilizing an Immobilized Enzyme 582\u003c\/p\u003e \u003cp\u003eMagnetic Separation of Proteins 582\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLarge-Scale Production of DNA and RNA 583\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePlasmid DNA 583\u003c\/p\u003e \u003cp\u003emRNA 586\u003c\/p\u003e \u003cp\u003eSummary 587\u003c\/p\u003e \u003cp\u003eReferences 587\u003c\/p\u003e \u003cp\u003eReview Questions 590\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. Genetic Engineering of Plants: Methodology 591\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePlant Transformation with the Ti Plasmid of A. tumefaciens 595\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTi Plasmid-Derived Vector Systems 597\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIncreasing Transformation Efficiency 601\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMicroprojectile Bombardment 603\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChloroplast Engineering 604\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eVery-High-Level Protein Expression 607\u003c\/p\u003e \u003cp\u003e\u003cb\u003eUse of Reporter Genes in Transformed Plant Cells 610\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eManipulation of Gene Expression in Plants 611\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTransient Gene Expression 611\u003c\/p\u003e \u003cp\u003ePlant Promoters 616\u003c\/p\u003e \u003cp\u003eManipulation of Genes in Plants 617\u003c\/p\u003e \u003cp\u003eFacilitating Protein Purification 621\u003c\/p\u003e \u003cp\u003eProtein Glycosylation 623\u003c\/p\u003e \u003cp\u003eGene Stacking 624\u003c\/p\u003e \u003cp\u003eCRISPR-Based Directed Evolution 625\u003c\/p\u003e \u003cp\u003ePolycistronic Gene Expression 626\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProduction of Marker-Free Transgenic Plants 626\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRemoving Marker Genes from Nuclear DNA 627\u003c\/p\u003e \u003cp\u003eRemoving Marker Genes from Chloroplast DNA 632\u003c\/p\u003e \u003cp\u003eSummary 633\u003c\/p\u003e \u003cp\u003eReferences 634\u003c\/p\u003e \u003cp\u003eReview Questions 636\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Transgenic Plants 637\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eInsect Resistance 637\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eBacillus thuringiensis Insecticidal Toxin 637\u003c\/p\u003e \u003cp\u003eIncreasing Expression of the B. thuringiensis Protoxin 642\u003c\/p\u003e \u003cp\u003eOther Strategies for Protecting Plants against Insects 645\u003c\/p\u003e \u003cp\u003ePreventing the Development of B. thuringiensis-Resistant Insects 652\u003c\/p\u003e \u003cp\u003eTargeting Aphids 657\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVirus Resistance 658\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eViral Coat Protein-Mediated Protection 658\u003c\/p\u003e \u003cp\u003eProtection by Expression of Other Genes 663\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHerbicide Resistance 668\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGlyphosate 669\u003c\/p\u003e \u003cp\u003eDicamba 672\u003c\/p\u003e \u003cp\u003eOther Herbicides 673\u003c\/p\u003e \u003cp\u003e\u003cb\u003eFungus and Bacterium Resistance 674\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTransgenic Plants 675\u003c\/p\u003e \u003cp\u003eRNAi and CRISPR\/Cas 681\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSalt and Drought Stress 682\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIncreasing Trehalose Production 683\u003c\/p\u003e \u003cp\u003eSequestering Sodium Ions 684\u003c\/p\u003e \u003cp\u003eDelaying Drought-Induced Senescence 685\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePhytoremediation 686\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eFruits and Flowers 688\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFlavr Savr Tomato 688\u003c\/p\u003e \u003cp\u003eLowering Ethylene Levels 688\u003c\/p\u003e \u003cp\u003eCRISPR Mutants 690\u003c\/p\u003e \u003cp\u003e\u003cb\u003eModification of Plant Nutritional Content 690\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAmino Acids 690\u003c\/p\u003e \u003cp\u003eLipids 692\u003c\/p\u003e \u003cp\u003eVitamins 695\u003c\/p\u003e \u003cp\u003eIron 698\u003c\/p\u003e \u003cp\u003eGluten 700\u003c\/p\u003e \u003cp\u003e\u003cb\u003eModification of Food Plant Taste and Appearance 701\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePreventing Discoloration 701\u003c\/p\u003e \u003cp\u003eStarch 703\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePlants as Bioreactors 706\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAntibodies 706\u003c\/p\u003e \u003cp\u003ePharmaceuticals and Vaccines 709\u003c\/p\u003e \u003cp\u003ePoly(3-Hydroxybutyric Acid) 710\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEdible Vaccines 711\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEdible Cholera Vaccines 712\u003c\/p\u003e \u003cp\u003eEdible E. coli Vaccines 714\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePlant Yield 716\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIncreasing Grain Yield 716\u003c\/p\u003e \u003cp\u003eIncreasing Harvest Index 716\u003c\/p\u003e \u003cp\u003eDecreasing Lignin Content 717\u003c\/p\u003e \u003cp\u003eDecreasing Pectin Content 720\u003c\/p\u003e \u003cp\u003eIncreasing Oxygen Content 722\u003c\/p\u003e \u003cp\u003eSummary 723\u003c\/p\u003e \u003cp\u003eReferences 724\u003c\/p\u003e \u003cp\u003eReview Questions 729\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Transgenic Animals 731\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTransgenic Animal Methodologies 733\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDNA Microinjection Method 733\u003c\/p\u003e \u003cp\u003eRetroviral Vector Method 736\u003c\/p\u003e \u003cp\u003eEngineered Embryonic Stem Cell Method 737\u003c\/p\u003e \u003cp\u003eSomatic Cell Nuclear Transfer for Transgenic Livestock 743\u003c\/p\u003e \u003cp\u003eGenome Editing with the CRISPR‐Cas System 744\u003c\/p\u003e \u003cp\u003eConditional Gene Modification with the Cre–loxP Recombination System 747\u003c\/p\u003e \u003cp\u003eControl of Transgene Expression with the Tetracycline‐Inducible System 749\u003c\/p\u003e \u003cp\u003eGene Knockdown by RNA Interference 754\u003c\/p\u003e \u003cp\u003e\u003cb\u003eTransgenic Animal Models of Human Diseases 756\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMouse Models of Alzheimer’s Disease 756\u003c\/p\u003e \u003cp\u003eMouse Model of Duchenne Muscular Dystrophy 759\u003c\/p\u003e \u003cp\u003eRabbit Models of Cardiovascular Disease 761\u003c\/p\u003e \u003cp\u003eZebrafish Melanoma Model 763\u003c\/p\u003e \u003cp\u003eNonhuman Primate Models of Neurodevelopmental\u003c\/p\u003e \u003cp\u003eDisorders 766\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnimal Bioreactors for Production of Recombinant Therapeutic Proteins 767\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eProduction of Recombinant Antithrombin in Goat Milk 768\u003c\/p\u003e \u003cp\u003eProduction of a Human Protease Inhibitor in Rabbits 770\u003c\/p\u003e \u003cp\u003eProduction of Therapeutic Proteins in Chicken Eggs 771\u003c\/p\u003e \u003cp\u003eProduction of Donor Organs in Pigs 773\u003c\/p\u003e \u003cp\u003e\u003cb\u003eEnhancing Production Traits of Food Animals 774\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDisease‐Resistant Livestock 774\u003c\/p\u003e \u003cp\u003eImproving Milk Quality 781\u003c\/p\u003e \u003cp\u003eIncreasing Muscle Mass in Cattle 782\u003c\/p\u003e \u003cp\u003eEnhancing Growth of Salmon 786\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGene Drives To Eradicate Vector\u003c\/b\u003e\u003cb\u003e‐\u003c\/b\u003e\u003cb\u003eTransmitted Diseases 787\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMalaria Vector Population Suppression 789\u003c\/p\u003e \u003cp\u003eDengue Fever Virus‐Resistant Mosquitoes 791\u003c\/p\u003e \u003cp\u003eReversal Drives 792\u003c\/p\u003e \u003cp\u003eSummary 795\u003c\/p\u003e \u003cp\u003eReferences 796\u003c\/p\u003e \u003cp\u003eReview Questions 797\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13. Molecular Biotechnology and Society 799\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDevelopment of Guidelines for Recombinant DNA Research 800\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDeliberate Release of Genetically Modified Microorganisms 802\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEnvironmental Concerns 802\u003c\/p\u003e \u003cp\u003eRegulations 803\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRegulation of Genetically Modified Foods 804\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFood Ingredients Produced by Genetically Engineered Microorganisms 804\u003c\/p\u003e \u003cp\u003eGenetically Modified Crops 807\u003c\/p\u003e \u003cp\u003eGenetically Engineered Livestock 810\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSocietal Concerns about Genetically Modified Foods 812\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAlteration of Nutritional Content of Food 812\u003c\/p\u003e \u003cp\u003ePotential for Introducing Toxins or Allergens into Food 816\u003c\/p\u003e \u003cp\u003ePotential for Transferring Transgenes from Food to Humans or Intestinal Microorganisms 819\u003c\/p\u003e \u003cp\u003eControversy about the Labeling of Genetically Modified Foods 820\u003c\/p\u003e \u003cp\u003eImpact of Genetically Engineered Crops on Biodiversity 822\u003c\/p\u003e \u003cp\u003eWho Benefits from the Production of Genetically Modified Foods? 824\u003c\/p\u003e \u003cp\u003eEnvironmental Benefits of Genetically Modified Crops 825\u003c\/p\u003e \u003cp\u003eHow Do Views about Genetically Engineered Organisms Impact Trade? 827\u003c\/p\u003e \u003cp\u003e\u003cb\u003eRegulation and Safety of Medical Products of Biotechnology 827\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eNew Biological Drugs 828\u003c\/p\u003e \u003cp\u003eGenetic and Genomic Testing 832\u003c\/p\u003e \u003cp\u003eEconomic Issues 835\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePatenting Biotechnology 837\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePatenting 838\u003c\/p\u003e \u003cp\u003ePatenting in Different Countries 839\u003c\/p\u003e \u003cp\u003ePatenting Nucleic Acid Sequences 841\u003c\/p\u003e \u003cp\u003ePatenting Living Organisms 842\u003c\/p\u003e \u003cp\u003ePatenting and Fundamental Research 844\u003c\/p\u003e \u003cp\u003eSummary 845\u003c\/p\u003e \u003cp\u003eReferences 846\u003c\/p\u003e \u003cp\u003eReview Questions 848\u003c\/p\u003e \u003cp\u003eAmino Acids of Proteins and Their Designations 851\u003c\/p\u003e \u003cp\u003eIndex 853 \u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Biology, life sciences [\u003ca title=\"See our other books on Biology, life sciences\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Biology,%20life%20sciences%20%5BPS%5D%22\"\u003ePS\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"ASM Press","offers":[{"title":"Brand New","offer_id":52173737722136,"sku":"9781683673644","price":86.67,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781683673644.jpg?v=1781169276","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/molecular-biotechnology-principles-and-applications-of-recombinant-dna-hardback-9781683673644","provider":"Freshly Printed Books","version":"1.0","type":"link"}